Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
12 "Dong Jun Lim"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Original Article
Thyroid
Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib
Chae A Kim, Mijin Kim, Meihua Jin, Hee Kyung Kim, Min Ji Jeon, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Dong Yeob Shin, Won Gu Kim
Endocrinol Metab. 2024;39(2):334-343.   Published online April 4, 2024
DOI: https://doi.org/10.3803/EnM.2023.1854
  • 2,131 View
  • 66 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR), serve as valuable prognostic indicators in various cancers. This multicenter, retrospective cohort study assessed the treatment outcomes of lenvatinib in 71 patients with radioactive iodine (RAI)-refractory thyroid cancer, considering the baseline inflammatory biomarkers.
Methods
This study retrospectively included patients from five tertiary hospitals in Korea whose complete blood counts were available before lenvatinib treatment. Progression-free survival (PFS) and overall survival (OS) were evaluated based on the median value of inflammatory biomarkers.
Results
No significant differences in baseline characteristics were observed among patients grouped according to the inflammatory biomarkers, except for older patients with a higher-than-median NLR (≥2) compared to their counterparts with a lower NLR (P= 0.01). Patients with a higher-than-median NLR had significantly shorter PFS (P=0.02) and OS (P=0.017) than those with a lower NLR. In multivariate analysis, a higher-than-median NLR was significantly associated with poor OS (hazard ratio, 3.0; 95% confidence interval, 1.24 to 7.29; P=0.015). However, neither the LMR nor the PLR was associated with PFS. A higher-than-median LMR (≥3.9) was significantly associated with prolonged OS compared to a lower LMR (P=0.036). In contrast, a higher-than-median PLR (≥142.1) was associated with shorter OS compared to a lower PLR (P=0.039).
Conclusion
Baseline inflammatory biomarkers can serve as predictive indicators of PFS and OS in patients with RAI-refractory thyroid cancer treated with lenvatinib.
Close layer
Corrigendum
Miscellaneous
Corrigendum: Correction of Acknowledgments. Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinol Metab. 2022;37(1):181-182.   Published online February 28, 2022
DOI: https://doi.org/10.3803/EnM.2022.104
Corrects: Endocrinol Metab 2021;36(2):359
  • 3,532 View
  • 120 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study
    Sungho Bea, Heejun Son, Jae Hyun Bae, Sun Wook Cho, Ju‐Young Shin, Young Min Cho
    Diabetes, Obesity and Metabolism.2024; 26(1): 108.     CrossRef
Close layer
Original Articles
Clinical Study
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinol Metab. 2021;36(2):359-364.   Published online March 23, 2021
DOI: https://doi.org/10.3803/EnM.2020.890
Correction in: Endocrinol Metab 2022;37(1):181
  • 6,705 View
  • 217 Download
  • 20 Web of Science
  • 19 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.
Methods
Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.
Conclusion
KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.

Citations

Citations to this article as recorded by  
  • Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines
    Min Joo Kim, Jae Hoon Moon, Eun Kyung Lee, Young Shin Song, Kyong Yeun Jung, Ji Ye Lee, Ji-hoon Kim, Kyungsik Kim, Sue K. Park, Young Joo Park
    Endocrinology and Metabolism.2024; 39(1): 47.     CrossRef
  • It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Kyeong Jin Kim
    Endocrinology and Metabolism.2024; 39(1): 95.     CrossRef
  • Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
    Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2024; 39(1): 152.     CrossRef
  • Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review
    Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2024; 39(1): 152.     CrossRef
  • Comparison of Patient-Reported Outcomes Between Active Surveillance and Immediate Lobectomy in Patients with Low-Risk Papillary Thyroid Microcarcinoma: Initial Findings from the KoMPASS Cohort
    Min Joo Kim, Hojeong Won, Won Bae Kim, Eun Kyung Lee, Chang Yoon Lee, Sun Wook Cho, Han-Sang Baek, Yong Sang Lee, Yea Eun Kang, Sun Wook Kim, Ho-Cheol Kang, Jeongmin Lee, Mijin Kim, Min Ji Jeon, Jae Hoon Moon
    Thyroid®.2024;[Epub]     CrossRef
  • Standardized Ultrasound Evaluation for Active Surveillance of Low-Risk Thyroid Microcarcinoma in Adults: 2024 Korean Society of Thyroid Radiology Consensus Statement
    Ji Ye Lee, Min Kyoung Lee, Hyun Kyung Lim, Chang Yoon Lee, Jin Yong Sung, Jung Hyun Yoon, Soo Yeon Han, Jung Hee Shin, Ji-hoon Kim, So Lyung Jung, Sae Rom Chung, Jung Hwan Baek, Dong Gyu Na
    Korean Journal of Radiology.2024; 25(11): 942.     CrossRef
  • Thyroid‐Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low‐Risk Papillary Thyroid Microcarcinoma in Adults
    Yasuhiro Ito, Akira Miyauchi, Makoto Fujishima, Takuya Noda, Tsutomu Sano, Takahiro Sasaki, Taketoshi Kishi, Tomohiko Nakamura
    World Journal of Surgery.2023; 47(2): 392.     CrossRef
  • Thyroid FNA cytology: The Eastern versus Western perspectives
    Mitsuyoshi Hirokawa, Manon Auger, Chan Kwon Jung, Fabiano Mesquita Callegari
    Cancer Cytopathology.2023; 131(7): 415.     CrossRef
  • To Screen or Not to Screen?
    Do Joon Park
    Endocrinology and Metabolism.2023; 38(1): 69.     CrossRef
  • Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
    Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
    Endocrinology and Metabolism.2023; 38(1): 93.     CrossRef
  • Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience
    Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Akihiro Miya, Naoyoshi Onoda, Minoru Kihara, Takuya Higashiyama, Hiroo Masuoka, Shiori Kawano, Takahiro Sasaki, Mitsushige Nishikawa, Shuji Fukata, Takashi Akamizu, Mitsuru Ito, Eijun Nishihara, Mako Hisakad
    Thyroid®.2023; 33(7): 817.     CrossRef
  • Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status
    Masashi Yamamoto, Akira Miyauchi, Yasuhiro Ito, Makoto Fujishima, Takahiro Sasaki, Takumi Kudo
    Thyroid®.2023; 33(10): 1182.     CrossRef
  • Cost-Effectiveness of Active Surveillance Compared to Early Surgery of Small Papillary Thyroid Cancer: A Retrospective Study on a Korean Population
    Han-Sang Baek, Jeonghoon Ha, Kwangsoon Kim, Jaseong Bae, Jeong Soo Kim, Sungju Kim, Dong-Jun Lim, Chulmin Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Optimal Cutoff Values of the Contact Angle of Tumor on Sonography System for Predicting Extrathyroidal Extension of Papillary Thyroid Carcinoma by Tumor Location
    Ik Beom Shin, Do Hoon Koo, Dong Sik Bae
    Clinical Medicine Insights: Oncology.2023;[Epub]     CrossRef
  • Thermal Ablation for Papillary Thyroid Microcarcinoma Located in The Isthmus: a Study With 3 Years Of Follow-Up
    Lin Zheng, Fang-yi Liu, Jie Yu, Zhi-gang Cheng, Xiao-ling Yu, Xiao-cong Dong, Zhi-yu Han, Ping Liang
    Future Oncology.2022; 18(4): 471.     CrossRef
  • Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000–2018)
    Elisa Pasqual, Julie Ann Sosa, Yingxi Chen, Sara J. Schonfeld, Amy Berrington de González, Cari M. Kitahara
    Thyroid.2022; 32(4): 397.     CrossRef
  • Management of Low-Risk Thyroid Cancers: Is Active Surveillance a Valid Option? A Systematic Review of the Literature
    Renato Patrone, Nunzio Velotti, Stefania Masone, Alessandra Conzo, Luigi Flagiello, Chiara Cacciatore, Marco Filardo, Vincenza Granata, Francesco Izzo, Domenico Testa, Stefano Avenia, Alessandro Sanguinetti, Andrea Polistena, Giovanni Conzo
    Journal of Clinical Medicine.2021; 10(16): 3569.     CrossRef
  • Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review
    Han-sang Baek, Chai-ho Jeong, Jeonghoon Ha, Ja-Seong Bae, Jeong-soo Kim, Dong-Jun Lim, Chul-Min Kim
    Cancer Management and Research.2021; Volume 13: 6721.     CrossRef
  • Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(4): 717.     CrossRef
Close layer
Clinical Study
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
Mijin Kim, Jee Hee Yoon, Jonghwa Ahn, Min Ji Jeon, Hee Kyung Kim, Dong Jun Lim, Ho-Cheol Kang, In Joo Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
Endocrinol Metab. 2020;35(3):587-594.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.687
  • 6,585 View
  • 157 Download
  • 15 Web of Science
  • 13 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Vandetanib is the most widely used tyrosine kinase inhibitor for the treatment of patients with advanced medullary thyroid cancer (MTC). However, only limited data regarding its use outside clinical trials are available. We aimed to evaluate the efficacy and safety of vandetanib in patients with advanced MTC in routine clinical practice.
Methods
In this multicenter retrospective study, 12 patients with locally advanced or metastatic MTC treated with vandetanib at four tertiary hospitals were included. The primary outcome was the objective response rate (ORR) based on the Response Evaluation Criteria in Solid Tumors. The progression-free survival (PFS), overall survival (OS), and toxicities were also evaluated.
Results
Eleven patients (92%) had distant metastasis and 10 (83%) had disease progression at enrollment. Partial response was observed in five patients (ORR, 42%) and stable disease lasting ≥24 weeks was reported in an additional five patients (83%). During the median 31.7 months of follow-up, disease progression was seen in five patients (42%); of these, two died due to disease progression. The median PFS was 25.9 months, while the median OS was not reached. All patients experienced adverse events (AEs) which were generally consistent with the known safety profile of vandetanib. Vandetanib was discontinued in two patients due to skin toxicity.
Conclusion
Consistent with the phase III trial, this study confirmed the efficacy of vandetanib for advanced MTC in terms of both ORR and PFS in the real-world setting. Vandetanib was well tolerated in the majority of patients, and there were no fatal AEs.

Citations

Citations to this article as recorded by  
  • Alternative and efficient one-pot three-component synthesis of substituted 2-aryl-4-styrylquinazolines/4-styrylquinazolines from synthetically available 1-(2-aminophenyl)-3-arylprop-2-en-1-ones: characterization and evaluation of their antiproliferative a
    Diego Fernando Rodríguez, Kelly Johanna Lipez, Elena Stashenko, Iván Díaz, Justo Cobo, Alirio Palma
    RSC Advances.2024; 14(29): 20951.     CrossRef
  • Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance
    Katerina Saltiki, George Simeakis, Olga Karapanou, Stavroula A. Paschou, Maria Alevizaki
    Endocrine.2023; 80(3): 570.     CrossRef
  • Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
    Han-Sang Baek, Jeonghoon Ha, Seunggyun Ha, Ja Seong Bae, Chan Kwon Jung, Dong-Jun Lim
    Current Oncology.2023; 30(3): 3020.     CrossRef
  • Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
    Nicolas Sahakian, Frédéric Castinetti, Pauline Romanet
    Cancers.2023; 15(19): 4865.     CrossRef
  • Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
    Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Targeted therapy and drug resistance in thyroid cancer
    Yujie Zhang, Zhichao Xing, Tianyou Liu, Minghai Tang, Li Mi, Jingqiang Zhu, Wenshuang Wu, Tao Wei
    European Journal of Medicinal Chemistry.2022; 238: 114500.     CrossRef
  • Daily Management of Patients on Multikinase Inhibitors’ Treatment
    Carla Colombo, Simone De Leo, Matteo Trevisan, Noemi Giancola, Anna Scaltrito, Laura Fugazzola
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview
    Cătălina Ionescu, Bogdan Oprea, Georgeta Ciobanu, Milena Georgescu, Ramona Bică, Garofiţa-Olivia Mateescu, Fidan Huseynova, Veronique Barragan-Montero
    Medicina.2022; 58(7): 903.     CrossRef
  • Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy
    Tobiloba C. Elebiyo, Damilare Rotimi, Ikponmwosa O. Evbuomwan, Rotdelmwa Filibus Maimako, Matthew Iyobhebhe, Oluwafemi Adeleke Ojo, Olarewaju M. Oluba, Oluyomi S. Adeyemi
    Cancer Treatment and Research Communications.2022; 32: 100620.     CrossRef
  • Current Guidelines for Management of Medullary Thyroid Carcinoma
    Mijin Kim, Bo Hyun Kim
    Endocrinology and Metabolism.2021; 36(3): 514.     CrossRef
  • Recent advances in precision medicine for the treatment of medullary thyroid cancer
    Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska, Barbara Jarzab
    Expert Review of Precision Medicine and Drug Development.2021; 6(5): 307.     CrossRef
  • Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro
    Mingming Han, Xiaodan Zhang, Zhize Ye, Jing Wang, Jianchang Qian, Guoxin Hu, Jianping Cai
    Chemico-Biological Interactions.2021; 350: 109700.     CrossRef
  • Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update
    Alice Nervo, Francesca Retta, Alberto Ragni, Alessandro Piovesan, Alberto Mella, Luigi Biancone, Marco Manganaro, Marco Gallo, Emanuela Arvat
    Critical Reviews in Oncology/Hematology.2021; 168: 103533.     CrossRef
Close layer
Special Articles
Miscellaneous
Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology
Jung Hee Kim, Hyun Wook Chae, Sang Ouk Chin, Cheol Ryong Ku, Kyeong Hye Park, Dong Jun Lim, Kwang Joon Kim, Jung Soo Lim, Gyuri Kim, Yun Mi Choi, Seong Hee Ahn, Min Ji Jeon, Yul Hwangbo, Ju Hee Lee, Bu Kyung Kim, Yong Jun Choi, Kyung Ae Lee, Seong-Su Moon, Hwa Young Ahn, Hoon Sung Choi, Sang Mo Hong, Dong Yeob Shin, Ji A Seo, Se Hwa Kim, Seungjoon Oh, Sung Hoon Yu, Byung Joon Kim, Choong Ho Shin, Sung-Woon Kim, Chong Hwa Kim, Eun Jig Lee
Endocrinol Metab. 2020;35(2):272-287.   Published online June 24, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.2.272
  • 11,990 View
  • 517 Download
  • 19 Web of Science
  • 23 Crossref
AbstractAbstract PDFPubReader   ePub   
Growth hormone (GH) deficiency is caused by congenital or acquired causes and occurs in childhood or adulthood. GH replacement therapy brings benefits to body composition, exercise capacity, skeletal health, cardiovascular outcomes, and quality of life. Before initiating GH replacement, GH deficiency should be confirmed through proper stimulation tests, and in cases with proven genetic causes or structural lesions, repeated GH stimulation testing is not necessary. The dosing regimen of GH replacement therapy should be individualized, with the goal of minimizing side effects and maximizing clinical improvements. The Korean Endocrine Society and the Korean Society of Pediatric Endocrinology have developed a position statement on the diagnosis and treatment of GH deficiency. This position statement is based on a systematic review of evidence and expert opinions.

Citations

Citations to this article as recorded by  
  • Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
    Ghina Tsurayya, Cut Alifiya Nazhifah, Muhammad Rahmat Pirwanja, Putri Oktaviani Zulfa, Muhammad Raihan Ramadhan Tatroman, Fajar Fakri, Muhammad Iqhrammullah
    Children.2024; 11(2): 227.     CrossRef
  • Efficacy, safety, and patient satisfaction of norditropin and sogroya in patients with growth hormone deficiency: a systematic review and meta-analysis of randomized controlled trials
    Obieda Altobaishat, Mohamed Abouzid, Mostafa Hossam El Din Moawad, Abdulrahman Sharaf, Yazan Al-Ajlouni, Tungki Pratama Umar, Abdallah Bani-salameh, Mohammad Tanashat, Omar Abdullah Bataineh, Abdulqadir J. Nashwan
    Endocrine.2024; 85(2): 545.     CrossRef
  • Growth Hormone Deficiency and Growth Hormone Stimulation Test
    胜彬 孙
    Advances in Clinical Medicine.2024; 14(06): 1587.     CrossRef
  • Clinical Management of Postoperative Growth Hormone Deficiency in Hypothalamic-Pituitary Tumors
    Pedro Iglesias
    Journal of Clinical Medicine.2024; 13(15): 4307.     CrossRef
  • Isolated Growth Hormone Deficiency
    Anastasia Ibba, Chiara Guzzetti, Lavinia Sanfilippo, Sandro Loche
    Endocrines.2024; 5(3): 341.     CrossRef
  • L‐DOPA Test in the Diagnosis of Childhood Short Stature: Evaluation of Growth Hormone Peaks Over Time
    Barbara Castelli, Rita De Santis, Simona Carrera, Marco Andrea Malanima, Salvatore De Masi, Stefano Stagi
    Endocrinology, Diabetes & Metabolism.2024;[Epub]     CrossRef
  • Hsa_circ_0002473 inhibits GH3 cell proliferation and GH secretion as a competitive endogenous RNA for has-miR-4645-3p
    Kaiyu Pan, Xiaoguang Jiang, Xiaohong Hu, Jianhua Zhan, Chengyue Zhang
    Journal of Pediatric Endocrinology and Metabolism.2024;[Epub]     CrossRef
  • Baseline Clinical Factors Associated with Cessation of Growth Hormone Therapy in Patients with Severe Growth Hormone Deficiency - Real World Evidence
    Nageswary Nadarajah, Emmanuel Ssemmondo, Shani Brooks, Remi Akinyombo, Kazeem Adeleke, Harshal Deshmukh, Thozhukat Sathyapalan
    International Journal of Endocrinology and Metabolism.2024;[Epub]     CrossRef
  • GHRH in diabetes and metabolism
    Charlotte Steenblock, Stefan R. Bornstein
    Reviews in Endocrine and Metabolic Disorders.2024;[Epub]     CrossRef
  • Evaluation of Adult Height in Patients with Non-Permanent Idiopathic GH Deficiency
    Agnese Murianni, Anna Lussu, Chiara Guzzetti, Anastasia Ibba, Letizia Casula, Mariacarolina Salerno, Marco Cappa, Sandro Loche
    Endocrines.2023; 4(1): 169.     CrossRef
  • The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma
    Sang Hee Park, Yun Jeong Lee, Jung-Eun Cheon, Choong Ho Shin, Hae Woon Jung, Young Ah Lee
    Annals of Pediatric Endocrinology & Metabolism.2023; 28(2): 107.     CrossRef
  • Continuous Glucose Monitoring: A Possible Aid for Detecting Hypoglycemic Events during Insulin Tolerance Tests
    Soo Yeun Sim, Moon Bae Ahn
    Sensors.2023; 23(15): 6892.     CrossRef
  • The risk patients with AGHD have of developing CVD
    Eisha Javed, Maha Zehra, Naz Elahi
    International Journal of Cardiology Cardiovascular Risk and Prevention.2023; 19: 200221.     CrossRef
  • Diagnosis of GH Deficiency Without GH Stimulation Tests
    Anastasia Ibba, Sandro Loche
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
    Yun Jeong Lee, Yunha Choi, Han-Wook Yoo, Young Ah Lee, Choong Ho Shin, Han Saem Choi, Ho-Seong Kim, Jae Hyun Kim, Jung Eun Moon, Cheol Woo Ko, Moon Bae Ahn, Byung-Kyu Suh, Jin-Ho Choi
    Endocrinology and Metabolism.2022; 37(2): 359.     CrossRef
  • A Radiomics-Based Model with the Potential to Differentiate Growth Hormone Deficiency and Idiopathic Short Stature on Sella MRI
    Taeyoun Lee, Kyungchul Song, Beomseok Sohn, Jihwan Eom, Sung Soo Ahn, Ho-Seong Kim, Seung-Koo Lee
    Yonsei Medical Journal.2022; 63(9): 856.     CrossRef
  • Phenotypic spectrum of patients with mutations in CHD7: clinical implications of endocrinological findings
    Ja Hye Kim, Yunha Choi, Soojin Hwang, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi
    Endocrine Connections.2022;[Epub]     CrossRef
  • Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
    Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2022; 37(6): 839.     CrossRef
  • Laron syndrome: clinic, diagnostics (а clinical case)
    P.M. Lіashuk, R.P. Lіashuk, N.I. Stankova, M.B. Kudina
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(3): 193.     CrossRef
  • Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
    Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan
    Endocrinology and Metabolism.2021; 36(2): 322.     CrossRef
  • Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
    Byung Kwan Park, Masashi Fujimori, Shu-Huei Shen, Uei Pua
    Endocrinology and Metabolism.2021; 36(3): 553.     CrossRef
  • Asian Conference on Tumor Ablation guidelines for renal cell carcinoma
    Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, Yi Wang
    Investigative and Clinical Urology.2021; 62(4): 378.     CrossRef
  • Diagnosis and Treatment of Adult Growth Hormone Deficiency
    Jung Hee Kim
    The Korean Journal of Medicine.2021; 96(5): 400.     CrossRef
Close layer
Hypothalamus and Pituitary gland
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung-Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong-Su Moon, Dong Jun Lim, Dong Yeob Shin, Se Hwa Kim, Min Jeong Kwon, Ha Young Kim, Jin Hwa Kim, Dong Sun Kim, Chong Hwa Kim
Endocrinol Metab. 2019;34(1):53-62.   Published online March 21, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.1.53
  • 7,664 View
  • 294 Download
  • 10 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   ePub   

The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

Citations

Citations to this article as recorded by  
  • Hydrogel-fiber-mesh-based 3D cell cultures: A new method for studying pituitary tumors
    Wooju Jeong, Sungrok Wang, Yumin Kim, Soohyun Lee, Minhu Huang, Jaeil Park, Myung-Han Yoon, Chang-Myung Oh, Cheol Ryong Ku
    Smart Materials in Medicine.2024; 5(2): 281.     CrossRef
  • Differential gene expression and pathway analysis in growth hormone-secreting pituitary tumors according to granulation pattern
    Kyungwon Kim, Yeongmin Kim, Se Hoon Kim, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Chang-Myung Oh, Cheol Ryong Ku
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias
    Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Carla Mihaela Tone, Daria Alexandra Hemes, Konstantinos Periferakis, Lamprini Troumpata, Ioana Anca Badarau, Cristian Scheau, Ana Caruntu, Ilinca Savulescu-Fiedler, Constantin Carun
    Current Issues in Molecular Biology.2024; 46(9): 9721.     CrossRef
  • Insulin-Like Growth Factor 1 as a Pillar in Acromegaly: From Diagnosis to Long-Term Management
    Mi Kyung Kim
    Endocrinology and Metabolism.2024; 39(5): 693.     CrossRef
  • Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association
    A Ram Hong, Ho-Cheol Kang
    Endocrinology and Metabolism.2023; 38(2): 175.     CrossRef
  • Growth Hormone Excess: Implications and Management
    Suneela Dhaneshwar, Shrishti Shandily, Vatsalya Tiwari
    Endocrine, Metabolic & Immune Disorders - Drug Targets.2023; 23(6): 748.     CrossRef
  • Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
    Montserrat Marques-Pamies, Joan Gil, Elena Valassi, Marta Hernández, Betina Biagetti, Olga Giménez-Palop, Silvia Martínez, Cristina Carrato, Laura Pons, Rocío Villar-Taibo, Marta Araujo-Castro, Concepción Blanco, Inmaculada Simón, Andreu Simó-Servat, Gemm
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Evaluation and Management of Bone Health in Patients with Thyroid Diseases: a Position Statement from the Korean Thyroid Association
    A Ram Hong, Hwa Young Ahn, Bu Kyung Kim, Seong Hee Ahn, So Young Park, Min-Hee Kim, Jeongmin Lee, Sun Wook Cho, Ho-Cheol Kang
    International Journal of Thyroidology.2022; 15(1): 1.     CrossRef
  • Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy
    I. A. Ilovayskaya
    Meditsinskiy sovet = Medical Council.2022; (10): 148.     CrossRef
  • Approach of Acromegaly during Pregnancy
    Alexandru Dan Popescu, Mara Carsote, Ana Valea, Andreea Gabriela Nicola, Ionela Teodora Dascălu, Tiberiu Tircă, Jaqueline Abdul-Razzak, Mihaela Jana Țuculină
    Diagnostics.2022; 12(11): 2669.     CrossRef
  • Left to themselves: Time to target chronic pain in childhood rare diseases
    Christine B. Sieberg, Alyssa Lebel, Erin Silliman, Scott Holmes, David Borsook, Igor Elman
    Neuroscience & Biobehavioral Reviews.2021; 126: 276.     CrossRef
  • Severe respiratory failure in a patient with COVID-19 and acromegaly: rapid improvement after adding octreotide
    Jacob Luty, LesleAnn Hayward, Melanie Jackson, P Barton Duell
    BMJ Case Reports.2021; 14(8): e243900.     CrossRef
  • Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?
    Cheol Ryong Ku, Vladimir Melnikov, Zhaoyun Zhang, Eun Jig Lee
    Endocrinology and Metabolism.2020; 35(2): 206.     CrossRef
  • Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
    Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung-Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong-Su Moon, Dong
    The Korean Journal of Medicine.2019; 94(6): 485.     CrossRef
Close layer
Response
Thyroid
Response: Natural Course of Cytologically Benign Thyroid Nodules: Observation of Ultrasonographic Changes (Endocrinol Metab 2013;28:110-8, Dong Jun Lim et al.)
Dong Jun Lim, Ki Hyun Baek
Endocrinol Metab. 2013;28(3):243-244.   Published online September 13, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.3.243
  • 3,264 View
  • 24 Download
  • 1 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Calcification Patterns in Papillary Thyroid Carcinoma are Associated with Changes in Thyroid Hormones and Coronary Artery Calcification
    Jeonghoon Ha, Jeongmin Lee, Kwanhoon Jo, Jeong-Sun Han, Min-Hee Kim, Chan Jung, Moo Kang, Bong Cha, Dong-Jun Lim
    Journal of Clinical Medicine.2018; 7(8): 183.     CrossRef
Close layer
Original Article
Thyroid
Natural Course of Cytologically Benign Thyroid Nodules: Observation of Ultrasonographic Changes
Dong Jun Lim, Jee Young Kim, Ki Hyun Baek, Mee Kyoung Kim, Woo Chan Park, Jong Min Lee, Moo Il Kang, Bong Yun Cha
Endocrinol Metab. 2013;28(2):110-118.   Published online June 18, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.2.110
  • 5,023 View
  • 37 Download
  • 18 Web of Science
  • 23 Crossref
AbstractAbstract PDFPubReader   
Background

The natural course of cytologically benign thyroid nodules remains unclear. The aim of this study was to evaluate whether ultrasonographic (US) changes are associated with changes in nodule volume during follow-up.

Methods

We retrospectively reviewed over 4 years of clinical records of patients with benign thyroid nodules as confirmed by fine needle aspiration (FNA). In total, 186 patients with 202 benign thyroid nodules were included for study. We assessed for changes in nodule volume and examined the cystic portion of the nodule as well as four US features (echogenicity, margin, calcification pattern, and shape).

Results

During follow-up (mean, 21.7±10.7 months) and using 50% as a cutoff value, nodule volumes increased in 11.8%, exhibited no change in 79.9%, and decreased in 8.3% of patients. Proportion of nodules demonstrating at least one US change was 20.8% (42/202). The most common US changes (in descending order of frequency) were cystic change, margin change, and calcification pattern change. Nodule shape and echogenicity rarely changed. Increased nodule volume was not significantly associated with any US features or with the number of FNAs but was associated with younger age at time of diagnosis.

Conclusion

Although a portion of thyroid nodules confirmed as benign showed US changes or volume changes during the follow-up period, these findings may only represent the natural course of benign nodules. Frequent follow-up with US might be needed for only a small number of cases with suspicious US findings.

Citations

Citations to this article as recorded by  
  • Follow-up of benign thyroid nodules confirmed by ultrasound-guided core needle biopsy after inconclusive cytology on fine-needle aspiration biopsy
    Yoon Ji Hwang, Hye Ryoung Koo, Jeong Seon Park
    Ultrasonography.2023; 42(1): 121.     CrossRef
  • Clinical Characteristics, Diagnostic Approach and Outcome of Thyroid Incidental Findings vs. Clinically Overt Thyroid Nodules: An Observational Single-Centre Study
    Tom Jansen, Nike Stikkelbroeck, Annenienke van de Ven, Ilse van Engen-van Grunsven, Marcel Janssen, Han Bonenkamp, Martin Gotthardt, Romana T. Netea-Maier
    Cancers.2023; 15(8): 2350.     CrossRef
  • Association between various thyroid gland diseases, TSH values and thyroid cancer: a case–control study
    Leif Schiffmann, Karel Kostev, Matthias Kalder
    Journal of Cancer Research and Clinical Oncology.2020; 146(11): 2989.     CrossRef
  • TI-RADS und andere sonografische Klassifikationssysteme für Schilddrüsenknoten
    Julian M. M. Rogasch, Christoph Wetz, Winfried Brenner
    Onkologie up2date.2020; 2(03): 223.     CrossRef
  • TI-RADS und andere sonografische Klassifikationssysteme für Schilddrüsenknoten
    Julian M.M. Rogasch, Christoph Wetz, Winfried Brenner
    Radiopraxis.2020; 13(01): E1.     CrossRef
  • Changes of Nodular Size and Its Risk Factors in Iodine-Sufficient Area: a Retrospective Cohort Analysis of 7753 Thyroid Nodules
    Hwa Young Ahn, Kyung Won Kim, Hoon Sung Choi, Jae Hoon Moon, Ka Hee Yi, Min Kyung Hyun, Min Joo Kang, Jung Im Shim, Ja Youn Lee, Do Joon Park, Young Joo Park
    International Journal of Thyroidology.2020; 13(2): 118.     CrossRef
  • Comparison of Natural Course between Thyroid Cancer Nodules and Thyroid Benign Nodules
    Kyun-Jin Yun, Jeonghoon Ha, Min-Hee Kim, Ye Young Seo, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek
    Endocrinology and Metabolism.2019; 34(2): 195.     CrossRef
  • Risk factors for hypothyroidism in euthyroid thyroid nodule patients with lymphocytic thyroiditis on fine needle aspiration cytology
    Jeong-Min Lee, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Min-Hee Kim, Chan-Kwan Jung, So-Lyung Jung, Moo-Il Kang, Bong-Yun Cha, Dong-Jun Lim
    The Korean Journal of Internal Medicine.2019; 34(6): 1287.     CrossRef
  • Evaluation of the natural course of thyroid nodules in patients with acromegaly
    Sema Ciftci Dogansen, Artur Salmaslioglu, Gulsah Yenidunya Yalin, Seher Tanrikulu, Sema Yarman
    Pituitary.2019; 22(1): 29.     CrossRef
  • TI-RADS und andere sonografische Klassifikationssystemefür Schilddrüsenknoten
    Julian M.M. Rogasch, Christoph Wetz, Winfried Brenner
    Der Nuklearmediziner.2019; 42(03): 206.     CrossRef
  • Molecular profiling of thyroid nodule fine-needle aspiration cytology
    Markus Eszlinger, Lorraine Lau, Sana Ghaznavi, Christopher Symonds, Shamir P. Chandarana, Moosa Khalil, Ralf Paschke
    Nature Reviews Endocrinology.2017; 13(7): 415.     CrossRef
  • Diagnostic accuracy of thyroid nodule growth to predict malignancy in thyroid nodules with benign cytology: systematic review and meta‐analysis
    Naykky Singh Ospina, Spyridoula Maraka, Ana Espinosa DeYcaza, Derek O'Keeffe, Juan P. Brito, Michael R. Gionfriddo, M. Regina Castro, John C. Morris, Patricia Erwin, Victor M. Montori
    Clinical Endocrinology.2016; 85(1): 122.     CrossRef
  • Rapid thyroid nodule growth is not a marker for well-differentiated thyroid cancer
    Claudius Falch, Steffen Axt, Bettina Scuffi, Alfred Koenigsrainer, Andreas Kirschniak, Sven Muller
    World Journal of Surgical Oncology.2015;[Epub]     CrossRef
  • Predicting the Size of Benign Thyroid Nodules and Analysis of Associated Factors That Affect Nodule Size
    Seok Ho Seo, Tae Hyun Kim, Soon Ho Kim, Seung Hyun Lee, Jong Taek Kim, Dae Won Park, Dong Chul Lee
    Chonnam Medical Journal.2015; 51(2): 97.     CrossRef
  • Thyroid ultrasound findings in a follow-up survey of children from three Japanese prefectures: Aomori, Yamanashi and Nagasaki
    Naomi Hayashida, Misa Imaizumi, Hiroki Shimura, Fumihiko Furuya, Noriyuki Okubo, Yasushi Asari, Takeshi Nigawara, Sanae Midorikawa, Kazuhiko Kotani, Shigeyuki Nakaji, Akira Ohtsuru, Takashi Akamizu, Masafumi Kitaoka, Shinichi Suzuki, Nobuyuki Taniguchi, S
    Scientific Reports.2015;[Epub]     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
  • Natural Course of Cytologically Diagnosed Benign Thyroid Nodules
    Eun-Kyung Kim
    Journal of Korean Thyroid Association.2014; 7(2): 136.     CrossRef
  • Ruling in or ruling out thyroid malignancy by molecular diagnostics of thyroid nodules
    Markus Eszlinger, László Hegedüs, Ralf Paschke
    Best Practice & Research Clinical Endocrinology & Metabolism.2014; 28(4): 545.     CrossRef
  • Insufficient Experience in Thyroid Fine-Needle Aspiration Leads to Misdiagnosis of Thyroid Cancer
    Jung Il Son, Sang Youl Rhee, Jeong-taek Woo, Won Seo Park, Jong Kyu Byun, Yu-Jin Kim, Ja Min Byun, Sang Ouk Chin, Suk Chon, Seungjoon Oh, Sung Woon Kim, Young Seol Kim
    Endocrinology and Metabolism.2014; 29(3): 293.     CrossRef
  • Clinical Outcomes in Patients with Non-Diagnostic Thyroid Fine Needle Aspiration Cytology: Usefulness of the Thyroid Core Needle Biopsy
    Sung Hak Lee, Min Hee Kim, Ja Seong Bae, Dong Jun Lim, So Lyung Jung, Chan Kwon Jung
    Annals of Surgical Oncology.2014; 21(6): 1870.     CrossRef
  • Letter: Natural Course of Cytologically Benign Thyroid Nodules: Observation of Ultrasonographic Changes (Endocrinol Metab 2013;28:110-8, Dong Jun Lim et al.)
    Sun Wook Cho
    Endocrinology and Metabolism.2013; 28(3): 241.     CrossRef
  • Natural Course of Benign Thyroid Nodules
    Kyung Won Kim
    Endocrinology and Metabolism.2013; 28(2): 94.     CrossRef
  • Response: Natural Course of Cytologically Benign Thyroid Nodules: Observation of Ultrasonographic Changes (Endocrinol Metab 2013;28:110-8, Dong Jun Lim et al.)
    Dong Jun Lim, Ki Hyun Baek
    Endocrinology and Metabolism.2013; 28(3): 243.     CrossRef
Close layer
Case Reports
Pregnancy-induced Osteoporosis Combined with Multiple Compression Fractures: A Case Report.
Ji Eun Lee, Jin Sun Jang, Sun Hee Ko, Min Hee Kim, Dong Jun Lim, Moo Il Kang, Bong Yun Cha, Sook Hee Hong, Ja seong Bae, Kyeoung Sik Ryu
Endocrinol Metab. 2011;26(2):150-154.   Published online June 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.2.150
  • 2,404 View
  • 28 Download
  • 1 Crossref
AbstractAbstract PDF
Pregnancy associated osteoporosis (PAO) is a rare condition. It may affect women during pregnancy or after the delivery and it can induce severe back pain. Physicians can find multiple compression fractures on the plain images of these patients. However, little is known about PAO, including the prevalence, the cause, the risk factors and the prognosis. Herein we report on a case of PAO in a 38-year-old female who suffered from severe back pain induced by multiple vertebral compression fractures. After excluding the possibility of unknown malignancy, the patient underwent vertebroplasty to improve the clinical symptom. The bone biopsy results confirmed multiple benign acute compression fractures. The patient was treated with oral bisphosphonate, calcium and vitamin D. She showed clinical improvement without developing any additional vertebral fracture. When young women during pregnancy or just after the delivery complain of persistent back pain, PAO should be considered in the differential diagnosis, and early recognition and treatment are needed for PAO.

Citations

Citations to this article as recorded by  
  • Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures
    Eun Yeong Choe, Je Eun Song, Kyeong Hye Park, Hannah Seok, Eun Jig Lee, Sung-Kil Lim, Yumie Rhee
    Journal of Bone and Mineral Metabolism.2012; 30(5): 596.     CrossRef
Close layer
A Case of Pituitary Abscess that was Difficult to Diagnose due to Repeated Symptomatic Responses to Every Corticosteroid Administration.
Jin Sun Jang, Jae Seung Yun, Jung Ah Shin, Min Hee Kim, Dong Jun Lim, Jae Hyung Cho, Kun Ho Yoon, Moo Il Kang, Bong Yun Cha, Ho Young Son, Yong Kil Hong
Endocrinol Metab. 2011;26(1):72-77.   Published online March 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.1.72
  • 1,886 View
  • 24 Download
AbstractAbstract PDF
Pituitary abscess is a rare pathology, but it is a potentially life-threatening condition. Therefore, timely intervention, including antibiotics and an operation, can prevent the morbidity and mortality in such cases. A 31-year-old woman, who was 16 months after her second delivery, presented with intermittent headache for 3 months. Amenorrhea, polyuria and polydipsia were noticed and the endocrinological hormone studies were compatible with panhypopituitarism and diabetes insipidus. Pituitary MRI demonstrated a 2.3 cm sized cystic mass with an upper small nodular lesion. Her symptoms such as headache and fever were repeatedly improved whenever corticosteroid was administered, which led us to suspect the diagnosis of an inflammatory condition like lymphocytic hypophysitis. During the hormone replacement therapy, her cystic pituitary mass had grown and her symptoms progressively worsened for another two months. The patient underwent trans-sphenoidal exploration and she turned out to have a pituitary abscess. At the 3-month follow-up, amenorrhea was noticed and her residual function of the pituitary was tested by a combined pituitary stimulation test. The results were compatible with panhypopituitarism. She received levothyroxine 100 microg, prednisolone 5 mg and desmopressin spray and she is being observed at the out-patient clinic. The authors experienced a patient with primary pituitary abscess that was confirmed pathologically and we report on its clinical course with a literature review.
Close layer
Central Diabetes Insipidus Surmised as from Post-obstructive Diuresis after Decompression Treatment for Neurogenic Bladder.
Kang Woo Lee, Chul Woo Yang, Dong Jun Lim, Hyuk Sang Kwon, Mi Ja Kang, Eun Sook Kim, Kun Ho Yoon, Ho Young Son, Bong Yun Cha
J Korean Endocr Soc. 2009;24(2):144-147.   Published online June 1, 2009
DOI: https://doi.org/10.3803/jkes.2009.24.2.144
  • 2,443 View
  • 28 Download
  • 1 Crossref
AbstractAbstract PDF
Post-obstructive diuresis after treatment for neurogenic bladder-induced obstructive kidney disease is a common symptom. As polyuria may develop in many other conditions as well, the present case is about a patient with a chief complaint of polyuria accompanied by nocturia, that was initially diagnosed as hydronephrosis due to the presence of neurogenic bladder and bladder dysfunction. The result of the water deprivation test, which was conducted for persistent diluted polyuria, yielded a final diagnosis of central diabetes insipidus, notwithstanding the strong impression of post-obstructive diuresis initially made because of a sudden increase in urine output after an indwelling catheter was inserted for bladder decompression.

Citations

Citations to this article as recorded by  
  • A Case of Septo-Optic Dysplasia Resulting in Central Diabetes Insipidus and Nonobstructive Bilateral Hydronephrosis
    Jong Hyun Kim, Kwang Bok Lee, Jeonghun Lee, Soo Min Nam, Kang-Woo Lee, Eu Gene Hwang, Geon Gil
    Korean Journal of Medicine.2014; 87(2): 209.     CrossRef
Close layer
A Case of Graves' Disease Associated with Systemic Sclerosis.
Yune Jeong Lee, Mee Kyoung Kim, Dong Jun Lim, Ki Hoon Hur, Ki Hyun Baek, Moo Il Kang, Chul Soo Cho, Kwang Woo Lee, Gyeong Sin Park
J Korean Endocr Soc. 2007;22(3):220-224.   Published online June 1, 2007
DOI: https://doi.org/10.3803/jkes.2007.22.3.220
  • 2,354 View
  • 25 Download
  • 1 Crossref
AbstractAbstract PDF
Systemic sclerosis is associated with a broad spectrum of autoimmune thyroid diseases. The association between systemic scleroderma and hypothyroidism is well established. However, there have been very few reports concerning the association between hyperthyroidism and systemic scleroderma. We experienced a patient with Graves' disease who presented with muscle weakness and the patient was finally diagnosed with systemic sclerosis via pathological examination of the muscle. We describe here a rare case of systemic sclerosis associated with Graves` disease.

Citations

Citations to this article as recorded by  
  • Systemic Sclerosis Associated with Non-small Cell Lung Cancer and Papillary Thyroid Cancer: Case Report and Literature Review
    Ho Jae Kim, Jung Joo Kim, Hee Jung Park, Yong Tai Kim
    The Korean Journal of Medicine.2017; 92(3): 316.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP